KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
A natural history model of oesophageal adenocarcinoma to inform power calculations for the BEST4 screening trial.PMID 42647156 · 2026-Aug-26needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer.PMID 42636270 · 2026-Aug-24needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Investigating impact of a comprehensive support program on death anxiety among women with breast cancer: a clinical trial.PMID 42618834 · 2026-Aug-20needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Effectiveness of Theory-Based WhatsApp Chatbot Outreach in Colorectal Cancer Screening Uptake: A Randomized Controlled Trial.PMID 42617827 · 2026-Aug-19needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study.PMID 42617103 · 2026-Aug-18needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Effectiveness of oral cryotherapy in preventing methotrexate-induced oral mucositis in pediatric patients with acute lymphoblastic leukemia: a randomized controlled trial.PMID 42599331 · 2026-Aug-14needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial.PMID 42650704 · 2026-Aug-13needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Sanshimao Formula Improves Recurrence-Free Survival in Early and Intermediate Hepatocellular Carcinoma Patients with Cirrhosis: A Randomized Controlled Trial.PMID 42578431 · 2026-Aug-11needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Soluble suppression of tumorigenicity 2 (sST2) dynamics are associated with delayed hospital discharge in patients with COVID-19: a joint-modelling analysis of the DisCoVeRy trial's longitudinal data.PMID 42567228 · 2026-Aug-07needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Integrated narrative and cognitive therapy enhances psychological and functional recovery after ultra-low sphincter-preserving surgery for low rectal cancer: A randomized controlled trial with exploratory oncologic outcomes.PMID 42887071 · 2026-Aug-06needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Usability and relevance of specialized population-based cancer registry data in externally controlled trials.PMID 42556756 · 2026-Aug-05needs_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。pending-已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 - protocol.PMID 42551992 · 2026-Aug-04needs_reviewThis is a protocol for a randomized controlled trial, not a report of trial results. It does not present any formal efficacy data. The trial is randomized and drug-interventional (methadone) in an oncology setting, but it is a Phase II feasibility study (not Phase III), and it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoint is feasibility (completion rate), and secondary endpoints include pain intensity and quality of life, none of which are time-to-event endpoints requiring Kaplan-Meier analysis.pending-This is a protocol for a randomized controlled trial, not a report of trial results. It does not present any formal efficacy data. The trial is randomized and drug-interventional (methadone) in an oncology setting, but it is a Phase II feasibility study (not Phase III), and it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoint is feasibility (completion rate), and secondary endpoints include pain intensity and quality of life, none of which are time-to-event endpoints requiring Kaplan-Meier analysis.
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.PMID 42581230 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.PMID 42598868 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study.PMID 42623594 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.PMID 42635093 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.PMID 42666946 · 2026-Augneeds_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.PMID 42745627 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery.PMID 42770835 · 2026-Augneeds_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
An Evaluation of the Effect of Opioid-Free Anesthesia on Early Quality of Recovery in Patients Undergoing Gynecological Cancer Surgeries: A Randomized Controlled Trial.PMID 42701546 · 2026-Augneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.PMID 42525894 · 2026-Jul-29needs_reviewThe record describes a randomized, phase III, human oncology trial with primary results. However, it is excluded because (1) the intervention is a diagnostic/surveillance strategy (ctDNA-guided monitoring) without a drug-containing arm, and (2) the primary efficacy endpoint is not a time-to-event outcome but a categorical proportion of patients receiving therapy. Therefore, it does not meet the required criteria for inclusion.pending-The record describes a randomized, phase III, human oncology trial with primary results. However, it is excluded because (1) the intervention is a diagnostic/surveillance strategy (ctDNA-guided monitoring) without a drug-containing arm, and (2) the primary efficacy endpoint is not a time-to-event outcome but a categorical proportion of patients receiving therapy. Therefore, it does not meet the required criteria for inclusion.
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.PMID 42269244 · 2026-Jul-26eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma.PMID 42901914 · 2026-Jul-24needs_review已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。pending-已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.PMID 42485627 · 2026-Jul-23eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.PMID 42485700 · 2026-Jul-22eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.PMID 42480197 · 2026-Jul-21eligibleThe record explicitly describes a phase III randomized trial with a drug intervention, reporting final survival outcomes (OS, PFS) as time-to-event efficacy endpoints. All required criteria are established.needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer.PMID 42481259 · 2026-Jul-21eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.PMID 42483812 · 2026-Jul-21eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).PMID 42472751 · 2026-Jul-20eligibleOriginal Phase III randomized trial evaluating locoregional treatment versus systemic therapy in de novo metastatic breast cancer, with primary OS endpoint. The study is drug-containing (systemic therapy is the comparator and maintenance treatment).needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.PMID 42473802 · 2026-Jul-20needs_reviewThis is a protocol design paper for a Phase III randomized trial, not a report of formal results. The abstract describes the study rationale and design but does not present any efficacy data, including time-to-event endpoints such as OS, PFS, DFS, or associated Kaplan-Meier estimates or hazard ratios.pending-This is a protocol design paper for a Phase III randomized trial, not a report of formal results. The abstract describes the study rationale and design but does not present any efficacy data, including time-to-event endpoints such as OS, PFS, DFS, or associated Kaplan-Meier estimates or hazard ratios.
Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.PMID 42477876 · 2026-Jul-20eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.PMID 42418775 · 2026-Jul-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.PMID 42420599 · 2026-Jul-08eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).PMID 41968990 · 2026-Jul-06eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.PMID 42402625 · 2026-Jul-06eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.PMID 42551036 · 2026-Jul-03needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.PMID 42384869 · 2026-Jul-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.PMID 42620909 · 2026-Julneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Long-Term Dietary Changes and Mortality among Participants of a Whole Food Plant-Based Pilot Study for Metastatic Breast Cancer.PMID 42473551 · 2026-Julneeds_reviewThe record describes a long-term follow-up of a small pilot feasibility study of a dietary (whole food plant-based) intervention in metastatic breast cancer. It is a randomized study, but it is not a definitive Phase II/III or Phase III/IIIb trial, the intervention is non-drug, and the primary reported outcomes are mortality counts (not a formal time-to-event analysis with KM or HR) and dietary adherence, which is not an efficacy endpoint. Therefore, it does not meet the eligibility criteria.pending-The record describes a long-term follow-up of a small pilot feasibility study of a dietary (whole food plant-based) intervention in metastatic breast cancer. It is a randomized study, but it is not a definitive Phase II/III or Phase III/IIIb trial, the intervention is non-drug, and the primary reported outcomes are mortality counts (not a formal time-to-event analysis with KM or HR) and dietary adherence, which is not an efficacy endpoint. Therefore, it does not meet the eligibility criteria.
Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review.PMID 42473535 · 2026-Julneeds_reviewEligibility is uncertain because the record is a systematic review of multiple trials, not an original result report of a single randomized trial. While it involves oncology, human subjects, randomized trials, and a time-to-event endpoint, it does not meet the 'original_result' criterion. Drug intervention is not clearly the focus of an original trial report here.pending-Eligibility is uncertain because the record is a systematic review of multiple trials, not an original result report of a single randomized trial. While it involves oncology, human subjects, randomized trials, and a time-to-event endpoint, it does not meet the 'original_result' criterion. Drug intervention is not clearly the focus of an original trial report here.
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.PMID 41571044 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.PMID 41833903 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.PMID 41834413 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).PMID 41999978 · 2026-Juleligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.PMID 42025759 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.PMID 42047965 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.PMID 42127535 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.PMID 42166701 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.PMID 42167105 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.PMID 42202843 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。